Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acsptsci.0c00108 http://scihub22266oqcxt.onion/10.1021/acsptsci.0c00108 33062953!7507806!33062953     free     free     free Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 227.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ACS+Pharmacol+Transl+Sci 2020 ; 3 (5): 1008-1016 Nephropedia Template TP {{tp|p=33062953|t=2020. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening |pdf=|usr=}}{{33062953}} gab.com Text Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening JO: ACS Pharmacol Transl Sci http://www.kidney.de/pget.php?&tw=1&pmid=33062953 #FOAvip The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. The 3C-like protease (3CL(pro)), or main protease (M(pro)) of SARS-CoV-2 is a valid drug target as it is a specific viral enzyme and plays an essential role in viral replication. We performed a quantitative high-throughput screening (qHTS) of 10?755 compounds consisting of approved and investigational drugs, and bioactive compounds using a SARS-CoV-2 3CL(pro) assay. Twenty-three small molecule inhibitors of SARS-CoV-2 3CL(pro) have been identified with IC(50)s ranging from 0.26 to 28.85 muM. Walrycin B (IC(50) = 0.26 muM), hydroxocobalamin (IC(50) = 3.29 muM), suramin sodium (IC(50) = 6.5 muM), Z-DEVD-FMK (IC(50) = 6.81 muM), LLL-12 (IC(50) = 9.84 muM), and Z-FA-FMK (IC(50) = 11.39 muM) are the most potent 3CL(pro) inhibitors. The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds using a SARS-CoV-2 cytopathic effect assay. The results demonstrated a set of SARS-CoV-2 3CL(pro) inhibitors that may have potential for further clinical evaluation as part of drug combination therapies to treating COVID-19 patients and as starting points for chemistry optimization for new drug development. Twit Text FOAVip Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening ????ACS Pharmacol Transl Sci http://www.kidney.de/pget.php?&tw=1&pmid=33062953 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33062953 #FOAvip English Wikipedia <ref>{{Cite pmid|33062953}}</ref> Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening #MMPMID33062953 Zhu W; Xu M; Chen CZ; Guo H; Shen M; Hu X; Shinn P; Klumpp-Thomas C; Michael SG; Zheng W ACS Pharmacol Transl Sci 2020[Oct]; 3 (5): 1008-1016 PMID33062953show ga The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has emphasized the urgency to develop effective therapeutics. Drug repurposing screening is regarded as one of the most practical and rapid approaches for the discovery of such therapeutics. The 3C-like protease (3CL(pro)), or main protease (M(pro)) of SARS-CoV-2 is a valid drug target as it is a specific viral enzyme and plays an essential role in viral replication. We performed a quantitative high-throughput screening (qHTS) of 10?755 compounds consisting of approved and investigational drugs, and bioactive compounds using a SARS-CoV-2 3CL(pro) assay. Twenty-three small molecule inhibitors of SARS-CoV-2 3CL(pro) have been identified with IC(50)s ranging from 0.26 to 28.85 muM. Walrycin B (IC(50) = 0.26 muM), hydroxocobalamin (IC(50) = 3.29 muM), suramin sodium (IC(50) = 6.5 muM), Z-DEVD-FMK (IC(50) = 6.81 muM), LLL-12 (IC(50) = 9.84 muM), and Z-FA-FMK (IC(50) = 11.39 muM) are the most potent 3CL(pro) inhibitors. The activity of the anti-SARS-CoV-2 viral infection was confirmed in 7 of 23 compounds using a SARS-CoV-2 cytopathic effect assay. The results demonstrated a set of SARS-CoV-2 3CL(pro) inhibitors that may have potential for further clinical evaluation as part of drug combination therapies to treating COVID-19 patients and as starting points for chemistry optimization for new drug development. äIdentification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative(epmc).pdf DeepDyve Pubget Overpricing